Background Primary cutaneous plasmacytoma (pcp) is a rare disease, with few studies to guide therapy. Our
INTRODUCTION
Primary cutaneous plasmacytoma (pcp) is a rare diagnosis, with fewer than 50 cases estimated to be have been reported and compiled in the literature [1] [2] [3] . Cutaneous deposits of plasma cells are more commonly seen in the context of multiple myeloma, where such deposits are associated with poor prognosis 4, 5 . However, because of good long-term outcomes, treatment for plasmacytoma is typically approached with curative intent; for solitary lesions, local treatments such as radiotherapy (rt) or surgery play an important role 6 . As well, compared with osseous plasmacytomas, soft-tissue plasmacytomas are associated with a lower rate of progression to multiple myeloma 7 . Plasmacytoma of the integumentary system (a non-osseous organ) is classified as an extramedullary plasmacytoma.
Because of pcp's rarity, little is known about its treatment, which can vary widely, ranging from surgical excision to systemic therapy and rt 1,2 . Furthermore, details of treatment are poorly described; many case reports focus only on the pathologic diagnosis 3, [8] [9] [10] [11] . Although extramedullar y plasmacytomas are associated with good clinical outcomes, patients with pcp can develop local recurrence, distant skin recurrence, or systemic progression to multiple myeloma 1, 2 . Some authors have suggested an association with improved clinical outcomes in patients with a solitary pcp lesion compared with multiple pcp lesions 1, [12] [13] [14] .
Because pcp is a rare disease, information to guide therapy is limited. In the present study, a retrospective chart review considered cancer registry data for all patients seen at a single institution. A systematic review of the literature provided further information about treatments and outcomes in pcp.
METHODS

Chart Review
In our single-institution retrospective chart review, patients with a single pcp lesion or multiple pcp lesions were included. Patients were excluded if they had synchronous involvement of bone, bone marrow, or lymph nodes; multiple myeloma at diagnosis of pcp; cutaneous manifestation of multiple myeloma; diagnosis of post-transplant lymphoproliferative disorder; poems syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes); aesop (adenopathy and extensive skin patch overlying a plasmacytoma); infectious or reactive causation (for example, insect bite or herpes simplex virus); or polyclonal plasma cell infiltrates. Patients were identified using the Princess Margaret Cancer Registry, which includes all patients with malignancy seen or treated at the Princess Margaret Cancer Centre dating back to 1958. Charts of identified patients were then reviewed to extract clinical details, pathology, treatment, response to therapy, follow-up, and vital status.
The primary objective of our study was to describe treatments used for pcp. Secondary objectives were to describe recurrence-free survival (rfs) and overall survival (os) in patients with pcp. The study was reviewed and approved by the University Health Network Research Ethics Board.
Systematic Review
In the systematic review, published articles were included if they described one or more patients with pcp. The inclusion and exclusion criteria were the same as those used in the chart review. No language restrictions were applied. A database search of medline was performed on 10 April 2015 using the search terms "exp Plasmacytoma/ and cutaneous.mp. and exp Skin/ or exp Skin Neoplasms/ or exp Carcinoma, Skin Appendage/ or skin.mp. or exp Skin Diseases/" and was limited to "humans" and "cancer." Full article texts were reviewed; if the text was unavailable, the article title and abstract was reviewed. Reference lists were screened for additional articles. Patient details (diagnosis, number of skin lesions, treatment, recurrence, vital status, and follow-up if available) were extracted from published articles and entered into a standardized data collection form. Cases were classified as "solitary" if the patient had an isolated single cutaneous plasmacytoma, with no other cutaneous or soft-tissue or osseous lesions; otherwise, the case was classified as "multiple." Pathologic diagnosis and histology were not a focus of this systematic review.
Statistics
The rfs was defined as time from pathologic diagnosis of the index lesion to recurrence or progression of plasmacytoma, development of multiple myeloma, or death. Persistent disease after treatment was counted as a recurrence at time of treatment. The os was defined as time from pathologic diagnosis of the index lesion to death. Patients lost to follow-up were censored. Kaplan-Meier curves were constructed for rfs and os. Univariate hazard ratios with 95% confidence intervals (cis) were calculated using a Cox proportional hazards model. All statistical analyses were performed using the SAS (version 9.4: SAS Institute, Cary, NC, U.S.A.) and R (version 3.2.2: The R Foundation, Vienna, Austria) software applications.
RESULTS
Chart Review
For the 3 eligible patients identified from the cancer registry (Table i) , median age was 48 years (range: 48-69 years). Each patient had a solitary pcp. One patient received surgery followed by adjuvant rt; the other two patients received definitive rt alone.
Patient 1
A 48-year-old man presented in May 1979 with a single lesion over the right scapula that had doubled in size since March. No constitutional symptoms were reported. The patient had a non-contributory past medical history, but was a heavy smoker and drinker. The subcutaneous tumour was surgically removed by wide local excision on 9 May 1979. The biopsy was signed out as a "malignant plasmacytoma with infiltration of skin and subcutaneous adipose tissue from back," with negative margins. Diagnostic investigations were negative for multiple myeloma, with no Bence Jones protein in urine, and normal serum calcium, albumin, total protein, creatinine (exact values not available), and hemoglobin (143 g/L). Serum protein electrophoresis did note a lambda immunoglobulin A spike; no bone marrow biopsy was obtained, however. Skeletal survey was normal.
Definitive rt was recommended, to a total dose of 25 Gy in 10 daily fractions, using cobalt-60 external-beam rt. Treatment was delivered using a single anterior field encompassing the right orbit, with a pencil eye shield to block the anterior chamber [ Figure 1 ]. Serum protein electrophoresis did not reveal any monoclonal protein spike; β 2 -microglobulin was 2.9 mg/L (normal range: 0.6-2.3 mg/L), and the free kappa/ lambda ratio was 1.38 (normal range: 0.26-1.65). Bone marrow biopsy was normal, with less than 5% plasma cells; no clonal restriction was observed, although incidental megakaryocytic thrombocytopenia was noted. Computed tomography imaging showed no lymphadenopathy or lytic lesions; skeletal survey showed no lytic lesions.
The patient received definitive rt to 35 Gy in 10 daily fractions delivered using orthovoltage X-rays (225 kVp). 
Systematic Review
The systematic review of the literature ( Figure 3 ) identified 66 eligible cases of pcp. Including the 3 patients from our chart review, 69 patients-35 of whom had a solitary pcp lesion-were analyzed (Table ii) . Table iv provides rt and chemotherapy details. The rt dose was specified for 15 of the 27 patients (56%) who received rt as a component of their pcp treatment. Three patients received palliative-intent rt (total dose: ≤20 Gy). Two patients received surgery and adjuvant radiation as primary treatment: the dose for one patient was unknown 17 , and it was 20 Gy in 5 fractions for the other (patient 1 in the present report). One patient received 50 Gy in 25 fractions to a left cheek primary, with no response; salvage surgery was subsequently performed 32 . As with radiation doses, chemotherapy regimens ranged widely; the most commonly used regimen was melphalan combined with a corticosteroid.
Of the patients with a known disease response to chemotherapy or rt, most experienced a complete clinical response ( Table v) . Of patients with known recurrence details, most had no disease recurrence (Table vi) . Among patients with a solitary pcp, 9 recurrences were observed.
Local recurrences in 2 patients were both initially treated with surgery 23, 31 . Distant skin recurrences in 5 patients were initially treated with surgery alone 32 , surgery and rt 17 , rt alone (2 patients) 2,64 , or chemotherapy alone 45 . Finally, 2 patients experienced a distant recurrence; those patients were initially treated with rt 44 or observation 58 . Among the 19 patients for whom information about time-to-recurrence was available, median time to recurrence was 7.0 months (range: 1-132 months), and mean time to recurrence was 17.4 months.
Among the 69 analyzed patients, 27 events (recurrence of plasmacytoma, development of multiple myeloma, or death) were reported ( Figure 4 ). Median rfs was 2.7 years (95% ci: 1.4 years to not reached), with 1-year, 2-year, and 5-year rfs estimates of 63%, 53%, and 44% respectively. Of those 27 events, 11 were observed in patients with a solitary pcp, with a median rfs of 11.0 years (95% ci: 2 years to not reached). The other 16 events were seen in patients with multiple lesions, with a median rfs of 1.4 years (95% ci: 0.6 years to not reached). The hazard ratio for rfs for patients with a solitary pcp lesion compared with those having multiple lesions was 0.47 (95% ci: 0.21 to 1.08; p = 0.069). No other variables were associated with rfs or os on univariate analysis (Table vii) .
Among the 19 patient deaths reported, 18 had a documented time from diagnosis to death ( Figure 4 ). The remaining patient was censored at last known follow-up 51 . Median os was 10.4 years (95% ci: 4.3 years to not reached), with 1-year, 2-year, and 5-year os estimates of 80%, 64%, and 59% respectively. In patients with a solitary pcp, 7 deaths were observed, with a median os of 17.0 years (95% ci: 1.7 years to not reached). In patients with multiple pcp lesions, 12 deaths were observed, with a median os of 4.3 years (95% ci: 1.3 years to not reached). The hazard ratio for os in patients with a solitary pcp lesion compared with those having multiple lesions was 0.37 (95% ci: 0.13 to 1.08; p = 0.059).
Table vi reports causes of death. Multiple myeloma was the most common cause of death, followed by recurrent plasma cell disease not meeting diagnostic criteria for multiple myeloma.
DISCUSSION
The present study represents the largest published single-institution case series of solitar y pcp, com- prising 3 cases in total. Yamamoto described 3 patients with multiple pcp lesions 52 . Three other articles have each described 2 patients with pcp 2,46,54 . Cases of reactive pcp, which are excluded from the present analysis, have also been reported, associated with stimulation from infectious agents such as herpes simplex virus or insect bites 67, 68 . The present systematic review summarizes all published nonreactive cases of pcp. The most recent comprehensive literature reviews of pcp were published by Muscardin et al. 1 (Figure 4) , although the data are limited by short follow-up and a small sample size.
As in the present analysis, earlier reviews of patients with pcp have reported a mean age of 60, with male predominance 1, 2, 31 . The lesions are often described as reddish or purple nodules or plaques without ulceration 2, 12, 31 . The most consistently reported prognostic factor is the number of lesions, with outcomes being better with solitary lesions than with multiple lesions at presentation 1, [12] [13] [14] . Solitary lesions tended to have less locoregional or distant dissemination and remained confined to the skin 1, 31 ; however, large solitary lesions might have a higher risk of Reported as a plasmacytoma, but staining for kappa and lambda chains was negative 29 . progression to metastatic disease (although a size cut-off is not defined) 1 . Patients with multiple lesions had a higher likelihood of progression to multiple myeloma and subsequent death 2,46,68 . Muscardin et al. 1 did not report any association of paraproteinemia with outcome. The present study accords with the prior finding that paraproteinemia is not associated with survival, although information about other variables associated with progression to multiple myeloma such as immunoglobulin levels or serum free light-chain ratio were not available.
Treatment of pcp should be individualized to the patient and tumour characteristics. In general, authors agreed that curative-intent local treatment-which can entail surgery, rt, or surgery followed by adjuvant rt-is appropriate for solitary pcp lesions 1, 9, 23, 31, 46 . Green et al. 68 cautioned that local recurrence or lymph node metastases could develop after local therapy. Patients with multiple pcp lesions are optimally treated with systemic chemotherapy 9 .
In the present analysis, it was not possible, because the wide range of dose and fractionations used, to draw conclusions about the efficacy of a specific rt dose. Recurrence data and site of recurrence were available but challenging to interpret because of the many patients whose recurrence status was unknown. Nonetheless, it is notable that the only local recurrences observed in patients with a solitary pcp lesion happened in patients initially treated with surgery alone.
The only clinical variable associated with rfs and os was the number of lesions (solitary vs. multiple), which showed a trend toward statistical significance. We observed a large difference in median survival (17 years vs. 4.3 years) and rfs (11.0 years vs. 1.4 years) between patients with solitary lesions and those with multiple lesions, albeit with overlapping cis. Based on those data, patients with solitary lesions are likely to have better outcomes, although that probability cannot be demonstrated to a p value of less than 0.05 because of the small number of events and the lack of long-term follow-up. Therapeutic approach (surgery vs. rt vs. chemotherapy) was not associated with rfs or os; however, our study was underpowered to detect a difference This patient had a 6-cm mass overlying the left cheek, biopsied as plasmacytoma. No Bence Jones protein was detected at diagnosis. Routine lab work, protein electrophoresis, and bone marrow biopsy were normal. This patient was treated with 50 Gy over 5 weeks with little shrinkage; surgery was then performed, but distant skin recurrence was seen 4 months after surgery. At the time of recurrence, bone marrow biopsy and serum protein electrophoresis remained normal. Chemotherapy was initiated; the patient progressed and died 22 months after diagnosis 8 . between treatments in the overall study population or in subgroups of patients with solitary or multiple lesions. The present study contributes to the literature by describing 3 additional patients with a solitary pcp (2 of whom have long-term follow-up) and by updating the systematic review of a rare disease to 69 total cases. However, the analysis is limited by the retrospective collection of published data and the extraction of details from articles. Given the elapsed time, contacting authors directly for further clinical data was infeasible. Epidermal and dermal involvement could not be distinguished. It is also possible that benign plasmacytoses were included in the analysis because information about monoclonality was not available for all reported cases; that limitation is acknowledged by Muscardin et al. 1 in their earlier review. Indeed, 3 of the historical patients in the review 15, 16, 18 could potentially have had benign tumours with plasma cell infiltrates or plasmacytic granulomas 23, 26, 31, 32, 49, 68 ; diagnosis requires careful histologic and immunohistochemical analysis 9 . Exclusion of the former 3 patients does not change the survival analysis, because follow-up for them was unavailable.
The results of this systematic review are subject to publication bias. A future approach could involve the use of population-level databases to provide accurate information about survival, but granularity of clinical data and treatment details is often unavailable with such an approach.
CONCLUSIONS
Primary cutaneous plasmacytoma is a rare diagnosis, with limited information to guide treatment. Here, 3 patients with a solitary pcp lesion are reported, with complete details about treatment. With the accompanying systematic review, a total of 69 patients with pcp are now reported in the literature. Most patients with a solitary pcp received rt as a component of treatment. A trend toward improved median rfs (11 years vs. 1.4 years) and os (17 years vs. 4.3 years) was observed in patients with a solitary pcp compared with those having multiple pcp lesions. Local treatment (such as rt or surgery) should be considered for patients with a solitary pcp; patients with multiple pcp lesions are likely to be best served by systemic chemotherapy. Treatment of pcp should be individualized depending on factors such as patient performance status, lesion count (solitary vs. multiple), and expected ability to tolerate treatment. The combination of surgery and radiation was excluded because of the small count (2 patients). HR = hazard ratio; CI = confidence interval.
